Refers to a Pharmaceutical composition for use in Spray Solution in a pressurized Metered Dose Inhaler comprising: (a) glycopyrronium bromide with a dosage between 5 and 26 UG Drive (b) formoterol, or a Salt thereof or a solvate of the Salt.With a Schedule between 1 and 25 ug Drive (c) a propellant consisting of a HFA (d) and (e) a cosolvent mineral acid as Stabilizer in a useful quantity. Said composition is contained in a spray can internally lined by a Resin which comprises a etileno\u2013propileno fluorinated Copolymer (FEP).In a Preferred aspect, the mineral acid is hydrochloric acid in an amount between 1m and 0.28 0.15 ug \/ ul as a Stabilizer and the co Solvent is ethanol.In Another aspect, the composition comprises one or more pharmaceutically Active Ingredients selected from beta\u20132 agonists corticosteroids inhaled (beclomethasone Dipropionate, budesonide, Fluticasone propionate, triamcinolone, prednisone, among others) Agen Tes Antimuscarinics, inhibitors and fosfodiesterasa\u20134.The storage of said composition in aluminum cans coated internally as has been pointed out previously, minimizes the amount of degradation products (particularly DP3) during its Shelf Life, even below the Threshold of Detection after Storage. The severe temperature and humidity.Se refiere a una composicion farmaceutica en solucion para aerosol para utilizar en un inhalador presurizado de dosis medida que comprende: a) bromuro de glicopirronio con una dosificacion entre 5 y 26 ug por accionamiento b) formoterol, o una sal del mismo o un solvato de dicha sal, con una dosificacion entre 1 y 25 ug por accionamiento c) un propelente que consiste en un HFA d) un cosolvente y e) un acido mineral como estabilizante en una cantidad util. Dicha composicion esta contenida en una lata de aerosol recubierta internamente por una resina que comprende un copolimero de etileno–propileno fluorado (FEP). En un aspecto preferido, el acido mineral es acido clorhidrico 1M, en una cantidad entre
